Bovine lactoferricin inhibits basic fibroblast growth factor- and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells

American Journal of Pathology

Volumn 169, Issue 5, 2006, Pages 1753-1766

  Mader, Jamie S ^a   Smyth, Daniel ^a   Marshall, Jean ^a   Hoskin, David W ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; HEPARIN; LACTOFERRICIN B; VASCULOTROPIN 165; COLLAGEN; FIBROBLAST GROWTH FACTOR 2; LACTOFERRIN; LAMININ; MATRIGEL; PROTEOGLYCAN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG BINDING; DRUG INHIBITION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BINDING COMPETITION; C57BL MOUSE; CATTLE; CELL MOTION; CELL SURVIVAL; CYTOLOGY; DRUG COMBINATION; DRUG EFFECT; METABOLISM; PROTEIN BINDING;

ANIMALS; BINDING, COMPETITIVE; CATTLE; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; COLLAGEN; DRUG COMBINATIONS; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; HEPARIN; HUMANS; LACTOFERRIN; LAMININ; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN BINDING; PROTEOGLYCANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38348999283     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.051229     Document Type: Article

References (60)

1. Baker EK, El-Osta A: MDR1, chemotherapy and chromatin remodeling. Cancer Biol Ther 2004, 3:819-824
2. Fayette J, Soria JC, Armand JP: Use of angiogenesis inhibitors in tumour treatment. Eur J Cancer 2005, 41:1109-1116
3. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257
4. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997, 94:8104-8109
5. Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 1992, 3:65-71
6. Javerzat S, Auguste P, Bikfalvi A: The role of fibroblast growth factors in vascular development. Trends Mol Med 2002, 8:483-489
7. Ribatti D: The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. Br J Haematol 2005, 128:303-309
8. Vlodavsky I, Fuks Z, Ishai-Michaeli R, Bashkin P, Levi E, Korner G, Bar-Shavit R, Klagsbrun M: Extracellular matrix-resident basic fibroblast growth factor: implication for the control of angiogenesis. J Cell Biochem 1991, 45:167-176
9. Cronauer MV, Hittmair A, Eder IE, Hobisch A, Culig Z, Ramoner R, Zhang J, Bartsch G, Reissigl A, Radmayr C, Thurnher M, Klocker H: Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate 1997, 31:223-233
10. Birck A, Kirkin AF, Zeuthen J, Hou-Jensen K: Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients. Melanoma Res 1999, 9:375-381
11. Kiriakidis S, Andreakos E, Monaco C, Foxwell B, Feldmann M, Paleolog E: VEGF expression in human macrophages is NF-κB-dependent: studies using adenoviruses expressing the endogenous NF-κB inhibitor IκBα and a kinase-defective form of the IκB kinase 2. J Cell Sci 2003, 116:665-674
12. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP: Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 1996, 56:2013-2016
13. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW: The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991, 5:1806-1814
14. 165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins. J Biol Chem 2005, 280:31508-31515
15. Rapraeger AC, Krufka A, Olwin BB: Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 1991, 252:1705-1708
16. Gitay-Goren H, Soker S, Vlodavsky I, Neufeld G: The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem 1992, 267:6093-6098
17. Brock JH: The physiology of lactoferrin. Biochem Cell Biol 2002, 80:1-6
18. Ward PP, Uribe-Luna S, Conneely OM: Lactoferrin and host defense. Biochem Cell Biol 2002, 80:95-102
19. Kanyshkova TG, Buneva VN, Nevinsky GA: Lactoferrin and its biological functions. Biochemistry (Mosc) 2001, 66:1-7
20. Hwang PM, Zhou N, Shan X, Arrowsmith CH, Vogel HJ: Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochemistry 1997, 37:4288-4298
21. Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M: Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J Appl Bacteriol 1992, 73:472-479
22. Andersen JM, Osbakk SA, Vorland LH, Traavik T, Guttenberg TJ: Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts. Antiviral Res 2001, 51:141-149
23. Bellamy W, Wakabayashi H, Takase M, Kawase K, Shimamura S, Tomita M: Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med Microbiol Immunol 1993, 182:97-105
24. Yoo YC, Watanabe R, Koike Y, Mitobe M, Shimazaki K, Watanabe S, Azuma I: Apoptosis induced in human leukemic cells by lactoferricin, a bovine milk protein-derived peptide: involvement of reactive oxygen species. Biochem Biophys Res Commun 1997, 237:624-628
25. Yoo YC, Watanabe S, Watanabe R, Hata K, Shimazaki KI, Azuma I: Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn J Cancer Res 1997, 88:184-190
26. Eliassen LT, Berge G, Sveinbjornsson B, Svendsen JS, Vorland LH, Rekdal Ø: Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res 2002, 22:2703-2710
27. Mader JS, Salsman J, Conrad DM, Hoskin DW: Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol Cancer Ther 2005, 4:612-624
28. Akhtar N, Dickerson EB, Auerbach R: The sponge/Matrigel angiogenesis assay. Angiogenesis 2002, 5:75-80
29. Wu HM, Church FC: Arginine 25 and arginine 28 of lactoferrin are critical for effective heparin neutralization in blood. Arch Biochem Biophys 2003, 412:121-125
30. Shimazaki K, Tazume T, Uji K, Tanaka M, Kumura H, Mikawa K, Shimo-Oka T: Properties of a heparin-binding peptide derived from bovine lactoferrin. J Dairy Sci 1998, 81:2841-2849
31. Travis PA, Bouill EG, Hamil B, Tindle BH: Detection of factor VIII von Willebrand factor in endothelial cells in first-trimester fetuses. Arch Pathol Lab Med 1988, 112:40-42
32. 51Cr release by isolated fat hepatocytes: an indicator of membrane damage. In Vitro 1978, 14:707-714
33. Yanagihara K, Tsumuraya M: Transforming growth factor β1 induces apoptotic cell death in cultured human gastric carcinoma cells. Cancer Res 1992, 52:4042-4045
34. Silvestri ME, Sundqvist VA: An investigation into the heparin-binding properties of a synthetic peptide deduced from the antigenic domain 2 of human cytomegalovirus glycoprotein B. Scand J Immunol 2001, 53:282-289
35. Norrby K, Mattsby-Baltzer I, Innocenti M, Tuneberg S: Orally administered bovine lactoferrin systemically inhibits VEGF(165)-mediated angiogenesis in the rat. Int J Cancer 2001, 91:236-240
36. Shimamura M, Yamamoto Y, Ashino H, Oikawa T, Hazato T, Tsuda H, Iigo M: Bovine lactoferrin inhibits tumor-induced angiogenesis. Int J Cancer 2004, 111:111-116
37. Kuwata H, Yip TT, Tomita M, Hutchens TW: Direct evidence of the generation in human stomach of an antimicrobial peptide domain (lactoferricin) from ingested lactoferrin. Biochem Biophys Acta 1998, 1429:129-141
38. Kuwata H, Yamauchi K, Teraguchi S, Ushida Y, Shimokawa Y, Toida T, Hayasawa H: Functional fragments of ingested lactoferrin are resistant to proteolytic digestion in the gastrointestinal tract of adult rats. J Nutr 2001, 131:2121-2127
39. Wakabayashi H, Kuwata H, Yamauchi K, Teraguchi S, Tamura Y: No detectable transfer of dietary lactoferrin or its functional fragments to portal blood in healthy adult rats. Biosci Biotechnol Biochem 2004, 68:853-860
40. Sanchez L, Aranda P, Perez MD, Calvo M: Concentration of lactoferrin and transferrin throughout lactation in cow's colostrums and milk. Biol Chem Hoppe Seyler 1988, 369:1005-1008
41. Yaffe EA, Nachman R, Becker C, Mimick R: Culture of human endothelial cells. Identification by morphologic and immunologic criteria. J Clin Invest 1973, 52:2745-2756
42. Chi JT, Chang HY, Haraldsen G, Jahnsen FL, Troyanskaya OG, Chang DS, Wang Z, Rockson SG, van de Rijn M, Botstein D, Brown PO: Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci USA 2003, 100:10623-10628
43. Lamszus K, Schmidt NO, Ergun S, Westphal M: Isolation and culture of human neuromicrovascular endothelial cells for the study of angiogenesis in vitro. J Neurosci Res 1999, 55:370-381
44. Nakatsu MN, Sainson RC, Aoto JN, Taylor KL, Aitkenhead M, Perezdel-Pulgar S, Carpenter PM, Hughes CC: Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and angiopoietin-1. Microvasc Res 2003, 66:102-112
45. Lohse DL, Linhardt RJ: Purification and characterization of heparin lyases from Flavobacterium heparinum. J Biol Chem 1992, 267:24347-24355
46. Desai UR, Wang H, Linhardt RJ: Substrate specificity of the heparin lyases from Flavobacterium heparinum. Arch Biochem Biophys 1993, 306:461-468
47. Andersen JH, Jenssen H, Sandvik K, Gutteberg TJ: Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulfate at the cell surface. J Med Virol 2004, 76:262-271
48. Di Biase AM, Pietrantoni A, Tinari A, Siciliano R, Valenti P, Antonini G, Seganti L, Superti F: Heparin-interacting sites of bovine lactoferrin are involved in anti-adenovirus activity. J Med Virol 2003, 69:495-502
49. 165. J Biol Chem 1999, 274:10816-10822
50. Qiao D, Meyer K, Mundhenke C, Drew SA, Friedl A: Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 signaling in brain endothelial cells. Specific role for glypican-1 in glioma angiogenesis. J Biol Chem 2003, 278:16045-16053
51. Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, Lander AD, Korc M: Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparinbinding growth factors in breast cancer cells. Cancer Res 2001, 61:5562-5569
52. Kleeff J, Ishiwata T, Kumbasar A, Friess H, Buchler MW, Lander AD, Korc M: The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest 1998, 102:1662-1673
53. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M: Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999, 68:729-777
54. Jenssen H, Andersen JH, Uhlin-Hansen L, Gutteberg TJ, Rekdal Ø: Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate. Antiviral Res 2004, 61:101-109
55. Stuckey JA, St Charles R, Edwards BF: A model of the platelet factor 4 complex with heparin. Proteins 1992, 14:277-287
56. Sunnergren KP, Fairman RP, deBlois GG, Glauser FL: Effects of protamine, heparinase, and hyaluronidase on endothelial permeability and surface charge. J Appl Physiol 1987, 63:1987-1992
57. Freeman C, Liu L, Banwell MG, Brown KJ, Bezos A, Ferro V, Parish CR: Use of sulfated linked cyclitols as heparan sulfate mimetics to probe the heparin/heparan sulfate binding specificity of proteins. J Biol Chem 2005, 280:8842-8849
58. Ran S, Downes A, Thorpe PE: Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 2002, 62:6132-6140
59. Papo N, Shai Y: Host defense peptides as new weapons in cancer treatment. Cell Mol Life Sci 2005, 62:784-790
60. Baker MA, Maloy WL, Zasloff M, Jacob LS: Anticancer efficacy of magainin 2 and analogue peptides. Cancer Res 1993, 53:3052-3057